Stepping up from ICS/LABA to FF/UMEC/VI in Patients with Uncontrolled Asthma: Outcomes from the 52-Week PERFORM Pragmatic Randomized Controlled Trial
Asthma remains uncontrolled in many patients receiving inhaled corticosteroid/long-acting β 2 -agonist (ICS/LABA), suggesting that guideline-recommended escalation to triple therapy is often delayed. We report outcomes in patients with uncontrolled, infrequently exacerbating asthma (understudied in traditional randomized controlled trials) stepping up from ICS/LABA to fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) from the PERFORM trial. PERFORM, a randomized, open-label, active-controlled, pragmatic trial in symptomatic adults with uncontrolled, infrequently exacerbating asthma, evaluated the effectiveness and safety of FF/UMEC/VI versus usual care ICS/LABA. Outcomes included trough forced expiratory volume in 1 s (FEV 1 ), asthma control (Asthma Control Questionnaire [ACQ-5/-6/-7]), and achieving clinical remission at Week 52 for the step-up (participants treated with ICS/LABA pre-randomization) and overall population. Safety was assessed throughout the study. Overall, 783 of 1236 participants in PERFORM received ICS/LABA pre-randomization, with 392 and 391 randomized to FF/UMEC/VI and ICS/LABA, respectively. Statistically significant improvements in trough FEV 1 were observed for FF/UMEC/VI versus ICS/LABA at Week 24 and were durable to Week 52 (least squares means treatment difference in change from baseline [95% confidence interval (CI)]: 66 ml [29, 103] and 67 ml [28, 106] at Weeks 24 and 52). FF/UMEC/VI showed greater odds of achieving ≥ 0.5-point improvement from baseline in ACQ-7 total score at Week 24 and achieving clinical remission at Week 52 versus ICS/LABA (adjusted odds ratio [95% CI]: 1.54 [1.12, 2.12] and 2.78 [1.82, 4.24]; not multiplicity adjusted). Results (including the Week 52 safety profile) were similar to the overall PERFORM population. Escalation to FF/UMEC/VI from ICS/LABA improved lung function, asthma control, and clinical remission, with no unexpected safety findings versus usual care ICS/LABA at Weeks 24 and 52, consistent with the overall PERFORM population. Initiation with FF/UMEC/VI may address the unmet need for optimized treatment in patients with uncontrolled, infrequently exacerbating asthma. Trial Registration : GSK ID: 219912/NCT06372496. Supplementary file1 (MP4 149035 KB)
Authors
- Hiroyuki Nagase (ORCID: https://orcid.org/0000-0002-0296-5901)
- Stephen G. Noorduyn (ORCID: https://orcid.org/0000-0002-5936-5579)
- John Oppenheimer (ORCID: https://orcid.org/0009-0002-3260-9630)
- Erika Penz
- Amila Poddar
- Nicola Brown
- Alison C Moore
- David Slade
- Gabriel Garcia
- Jodie Crawford
- Alan P. Baptist
Institutions
- Rutgers, The State University of New Jersey (US)
- Henry Ford Health System (US)
- GlaxoSmithKline (United Kingdom) (GB)
- Henry Ford Hospital (US)
- University of Saskatchewan (CA)
- GlaxoSmithKline (India) (IN)
- GlaxoSmithKline (United States) (US)
- GlaxoSmithKline (Canada) (CA)
- GlaxoSmithKline Research & Development Limited (United Kingdom) (GB)
- University of Medicine and Dentistry of New Jersey (US)
- Teikyo University (JP)
- McMaster University (CA)
Publication Details
- Journal
- Advances in Therapy
- Published
- 2026-11-16
- DOI
- https://doi.org/10.1007/s12325-026-03860-5
- Primary Topic
- Asthma and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00